Narrow search
Showing 1 - 10 of 1,437
Cover Image
Measuring Health-Related Quality of Life in Older Patient Populations: A Review of Current Approaches
Hickey, Anne; Barker, Maja; McGee, Hannah; O'Boyle, Ciaran - In: PharmacoEconomics 23 (2005) 10, pp. 971-993
The changing demographic profile of the world's population towards old age and evidence of people living for longer with less time spent in ill health highlight the importance of addressing quality-of-life (QOL) assessment issues for older people. The assessment of health-related QOL (HR-QOL)...
Persistent link: https://www.econbiz.de/10005243157
Cover Image
The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia
DiSantostefano, Rachael L.; Biddle, Andrea K.; Lavelle, … - In: PharmacoEconomics 24 (2006) 2, pp. 171-191
a managed-care claims database and Medicare fee schedules, and were reported in $US, 2004 values. Costs and …
Persistent link: https://www.econbiz.de/10005243187
Cover Image
Long-Term Cost-Effectiveness Analysis of Nebivolol Compared with Standard Care in Elderly Patients with Heart Failure: An Individual Patient-Based Simulation Model
Yao, Guiqing; Freemantle, Nick; Flather, Marcus; … - In: PharmacoEconomics 26 (2008) 10, pp. 879-889
elderly patients with heart failure compared with standard care. DOI: 10.2165/0019053-200826100-00007 … in elderly patients (e.g. >=70 years). This analysis evaluates the cost effectiveness of nebivolol compared with standard … and outcomes for nebivolol and standard care in patients with heart failure starting treatment at the age of 70 years …
Persistent link: https://www.econbiz.de/10004997789
Cover Image
Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza: Illustration for The Netherla...
Postma, Maarten J.; Novak, Annoesjka; Scheijbeler, Huib … - In: PharmacoEconomics 25 (2007) 6, pp. 497-509
vaccination and pandemic preparedness plans. Three patient subgroups were assessed (elderly patients [aged >=65 years] without … chronic disease, elderly patients with chronic disease, and chronically ill, non-elderly patients). Inputs for the model were … ill patients with ILI, visits to the GP for oseltamivir treatment were cost saving. For non-chronically ill elderly …
Persistent link: https://www.econbiz.de/10005448989
Cover Image
The Cost of Inadequate Prescriptions for Hypolipidaemic Drugs
Ballesteros, Luisa Cabello; San Martin, M. Isabel Fernandez - In: PharmacoEconomics 19 (2001) 5, pp. 513-522
being inadequately prescribed. Objective: To quantify the economic cost generated in 1 year in primary care by inadequate … programmes with both primary care physicians and specialists involved. …
Persistent link: https://www.econbiz.de/10005449034
Cover Image
Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada
Kohli, Michele; Attard, Cheryl; Lam, Annette; Huse, Daniel - In: PharmacoEconomics 24 (2006) 8, pp. 815-830
and long-term care for CAD events were included in the analysis. Costs ($Can, 2002 values) and outcomes were discounted at …
Persistent link: https://www.econbiz.de/10005449107
Cover Image
A Review of Quality of Life in Alzheimer's Disease: Part 1: Issues in Assessing Disease Impact
Walker, Melvyn D.; Salek, Sam S.; Bayer, Antony J. - In: PharmacoEconomics 14 (1998) 5, pp. 499-530
effectively using a practical administration technique that does not place any unnecessary burden on either informal carers, other …
Persistent link: https://www.econbiz.de/10005449174
Cover Image
Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed P...
Shih, Ya-Chen Tina; Bekele, Nebiyou B.; Xu, Ying - In: PharmacoEconomics 25 (2007) 10, pp. 843-862
compared the cost effectiveness of sertraline, citalopram, escitalopram and fluoxetine with paroxetine in elderly depressed …
Persistent link: https://www.econbiz.de/10005449194
Cover Image
Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model
Kreck, Simon; Klaus, Jochen; Leidl, Reiner; von … - In: PharmacoEconomics 26 (2008) 4, pp. 311-328
Background: Osteoporosis is a frequent complication in patients with inflammatory bowel disease. Recent studies have shown bisphosphonates to considerably reduce fracture risk in patients with osteoporosis, and preventing fractures with bisphosphonates has been reported to be cost effective in...
Persistent link: https://www.econbiz.de/10005449199
Cover Image
Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis: Ontario Ministry of Health Perspective
Marshall, John K.; Pellissier, James M.; Attard, Cheryl L. - In: PharmacoEconomics 19 (2001) 10, pp. 1039-1049
Background: Clinical trials have shown rofecoxib, a selective inhibitor of cyclo-oxygenase-2, to be associated with fewer gastrointestinal complications than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). Objective: To evaluate the potential clinical and economic consequences of...
Persistent link: https://www.econbiz.de/10005449240